CeriBell (CBLL) Stock Premium Rides High Margins Despite Deeper Losses

CeriBell stock rose 10.4% to US$21.31 after its Q2 print, as traders focused on headline growth in this high margin medical device story. Revenue reached US$28.1m and the company reported a net loss of US$19.3m, which keeps profitability in the future for now.

The key point for long term investors is the tension between that loss-making profile and the rich price to sales multiple, recently around 8x compared with peers closer to 6.8x. The rest of the earnings report outlines why the market is currently willing to pay this premium.

Is CeriBell’s 8x P/S multiple signaling justified growth potential or simply stretching the story too far? Compare the current market premium against fundamentals in our valuation analysis for CeriBell.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$28.1m vs. US$21.2m (revenue increased)
• Net Loss (Q2 2026 vs. Q2 2025): US$19.3m loss vs. US$13.6m loss (loss widened)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.51 loss per share vs. US$0.38 loss per share (loss per share widened)
• GAAP Gross Margin (Q2 2026): 92% reported, or 89% excluding a US$1.6m tariff refund (gross margin remained very high)

Prefer clean charts instead of another wall of earnings figures and margin percentages? See CeriBell’s full valuation picture in an easy visual format in our company report for CeriBell.

CeriBell growth story backed by revenue and adoption

CeriBell’s bullish narrative leans on high gross margins and growing hospital penetration. Q2 revenue of US$28.1m, with both product and subscription lines contributing, fits that picture. Active hospital accounts reached 712, and management pointed to more usage within existing sites alongside new account wins. The share price move of 10.4% on the day of the report and positive 7 day, 30 day and 90 day returns suggest investors are, for now, crediting this progress and the pipeline of cleared algorithms, new hardware and the planned delirium launch.

Losses, spending and execution keep the risk case alive

The bear case for CeriBell still has real support in the numbers. Net loss widened to US$19.3m and operating expenses rose 37% as the company invested in sales, R&D and legal. Adjusted EBITDA loss stayed close to US$10m and management is targeting cash flow break even using the current US$129.3m cash balance and expanded credit facility. Many of the bigger revenue swing factors, including delirium and neonate or pediatric offerings, are pushed into 2027, so execution over the next 12 to 18 months remains a key risk.

After widening losses and higher operating spend, are execution risks and insider selling just the visible issues, or early signs of deeper problems? Review the full risk analysis for CeriBell which shows 2 important warning signs.

Stay Ahead Of Your Next Move

If CeriBell’s high gross margins and widening losses have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story develops. Once you own CeriBell or any other stock, use the Portfolio Command Center to cut through noise and focus on the updates that really matter. For longer term decisions, tap into crowd insights and different investment angles through the Community. By surfacing potential catalysts and risks early, Simply Wall St helps you act with more confidence and stay a step ahead of the market.

Curious About Alternatives Worth Exploring

CeriBell might be on your screen today, but fresh stock ideas can start moving fast. Spot potential breakout momentum before it flies under the radar for now and get in early.

• Scan for potential bargains with strong foundations and springboard into a curated list of 51 high quality undervalued stocks before others catch the same setup, and use it while the data still feels fresh.
• Spot real businesses behind the crypto headlines and move early on a hand picked mix of 20 cryptocurrency and blockchain stocks while they are still under serious retail radar, then act decisively.
• Zero in on companies powering tomorrow’s grid and track a focused basket of 37 power grid technology and infrastructure stocks while valuations still reflect incomplete attention, then position before momentum builds.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com